or Try an Advanced Search...

    ETF Components for THNR - Amplify Weight Loss Drug & Treatment ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    LLY B -0.95 15.58
    NVO C -2.87 14.90
    AMGN B -0.45 5.57
    PFE D -0.47 5.32
    MRK C -1.46 5.02
    CTLT B 0.55 4.75
    TMO D 0.31 4.72

    Represented by ETF Holdings

    Keywords: S&P 500 Pharmaceutical Products Obesity Animal Health Biopharmaceutical Biotechnology Diabetes Health Products Inflammation Life Sciences Neuroscience Alzheimer's Disease Animal Health Products Antibiotics Clinic Depressive Disorder Dow Jones Component Dysfunction Erectile Dysfunction Growth Hormone
    Industries: Drug Manufacturers - Major Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic

    Recent News for Amplify Weight Loss Drug & Treatment ETF & its Holdings

    Date Stock Title
    Jul 3 LLY Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
    Jul 3 AMGN S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 NVO S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 LLY S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 NVO Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
    Jul 3 NVO Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 LLY Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 LLY Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 NVO Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 NVO Update: Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
    Jul 3 NVO Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study
    Jul 3 LLY ADP jobs data, Constellation Brands, summer gas prices: Morning Brief
    Jul 3 LLY Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 NVO Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 NVO Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
    Jul 3 LLY FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
    Jul 3 MRK Merck: Among The Best Health Care GARP Plays Today
    Jul 3 PFE GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines
    Jul 3 LLY Top 3 Health Care Stocks That May Crash This Quarter
    Jul 3 PFE Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
    The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
    Glucagon Glucagon Like Peptide 1 Peptide Therapeutics
    Back to the Main THNR Page...